Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors - Trial NCT02988843
Access comprehensive clinical trial information for NCT02988843 through Pure Global AI's free database. This Phase 2 trial is sponsored by Masonic Cancer Center, University of Minnesota and is currently Terminated. The study focuses on Germ Cell Tumor. Target enrollment is 1 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Masonic Cancer Center, University of Minnesota
Timeline & Enrollment
Phase 2
Mar 29, 2017
Dec 15, 2019
Primary Outcome
Disease Response Rate as Defined by the RECIST 1.1 Criteria, Integrated With Tumor Marker Response.
Summary
This is a multi-center phase II study of brentuximab vedotin in combination with bevacizumab
 for the treatment of refractory CD-30+ germ cell tumors (GCT) after disease progression on
 imaging and/or tumor marker progression documented by serially rising alpha-fetoprotein (AFP)
 or beta human chorionic gonadotropin (bHCG) measured on at least 2 consecutive visits and
 determined by treating physician to be clinically significant. Patients unable to receive 2nd
 line of platinum-based chemotherapy due to toxicity or refusal would also be eligible.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02988843
Non-Device Trial